Informações de ACADIA Pharmaceuticals Inc

Mais detalhes de ACADIA Pharmaceuticals Inc Empresa

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.



Código da empresaACAD

Nome da EmpresaACADIA Pharmaceuticals Inc

Data de listagemMay 27, 2004

CEOMs. Catherine Owen Adams

Número de funcionários653

Tipo de títulosOrdinary Share

Fim do ano fiscalMay 27

Endereço12830 El Camino Real

CidadeSAN DIEGO

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal92130

Telefone18585582871

Sitehttps://acadia.com/

Código da empresaACAD

Data de listagemMay 27, 2004

CEOMs. Catherine Owen Adams

Executivos da empresa ACADIA Pharmaceuticals Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Julian C. Baker

Independent Director

102.88K

--

Dr. Adora Ndu, Pharm.D.

Independent Director

24.80K

+60.90%

Ms. Laura A. Brege

Independent Director

15.10K

-48.90%

Mr. James Michael (Jim) Daly

Independent Director

--

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Chairman of the Board

--

Dr. Elizabeth H. Z. Thompson, Ph.D.

Executive Vice President and Head of Research and Development

--

Mr. Mark C. Schneyer

Chief Financial Officer, Executive Vice President

--

Dr. Edmund P. Harrigan

Independent Director

--

Mr. Thomas Andrew (Tom) Garner

Executive Vice President, Chief Commercial Officer

--

Ms. Catherine Owen Adams

Chief Executive Officer, Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Julian C. Baker

Independent Director

102.88K

--

Dr. Adora Ndu, Pharm.D.

Independent Director

24.80K

+60.90%

Ms. Laura A. Brege

Independent Director

15.10K

-48.90%

Mr. James Michael (Jim) Daly

Independent Director

--

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Chairman of the Board

--

Dr. Elizabeth H. Z. Thompson, Ph.D.

Executive Vice President and Head of Research and Development

--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q2

FY2023Q1

Por EmpresaUSD

Nome

Receita

Proporção

NUPLAZID

168.48M

63.68%

DAYBUE

96.09M

36.32%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

NUPLAZID

168.48M

63.68%

DAYBUE

96.09M

36.32%

Distribuição de ações

Atualizado em: qua, 8 de out

Investidores

Tipos de investidores

Investidores

Proporção

Baker Bros. Advisors LP

25.36%

BlackRock Institutional Trust Company, N.A.

10.77%

The Vanguard Group, Inc.

8.96%

RTW Investments L.P.

5.32%

State Street Investment Management (US)

3.65%

Outro

45.95%

Investidores

Proporção

Baker Bros. Advisors LP

25.36%

BlackRock Institutional Trust Company, N.A.

10.77%

The Vanguard Group, Inc.

8.96%

RTW Investments L.P.

5.32%

State Street Investment Management (US)

3.65%

Outro

45.95%

Tipos de investidores

Investidores

Proporção

Hedge Fund

36.76%

Investment Advisor

34.34%

Investment Advisor/Hedge Fund

25.10%

Research Firm

3.90%

Pension Fund

1.27%

Sovereign Wealth Fund

0.91%

Individual Investor

0.56%

Bank and Trust

0.34%

Venture Capital

0.06%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

670

173.25M

102.40%

-15.51M

2025Q2

671

174.83M

104.44%

-12.86M

2025Q1

688

177.74M

106.20%

-7.86M

2024Q4

643

167.35M

100.34%

-11.57M

2024Q3

599

161.17M

97.17%

-22.69M

2024Q2

603

166.04M

100.49%

-20.26M

2024Q1

612

167.37M

101.58%

-15.73M

2023Q4

589

164.89M

100.43%

-16.10M

2023Q3

560

161.37M

98.56%

-19.17M

2023Q2

557

164.35M

101.06%

-15.99M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Baker Bros. Advisors LP

42.90M

25.43%

+18.77K

+0.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

18.22M

10.8%

-552.34K

-2.94%

Jun 30, 2025

The Vanguard Group, Inc.

15.24M

9.03%

+61.01K

+0.40%

Jun 30, 2025

RTW Investments L.P.

9.00M

5.33%

+455.43K

+5.33%

Jun 30, 2025

State Street Investment Management (US)

6.18M

3.66%

-815.47K

-11.66%

Jun 30, 2025

Morgan Stanley & Co. LLC

3.19M

1.89%

-1.07M

-25.06%

Jun 30, 2025

Point72 Asset Management, L.P.

3.17M

1.88%

-1.48M

-31.74%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.02M

1.79%

+69.58K

+2.36%

Jun 30, 2025

Citadel Advisors LLC

3.01M

1.79%

+2.72M

+922.43%

Jun 30, 2025

Palo Alto Investors LP

2.56M

1.52%

-100.72K

-3.78%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

Alger Weatherbie Enduring Growth ETF

3.79%

iShares Neuroscience and Healthcare ETF

3.51%

First Trust NYSE Arca Biotechnology Index Fund

3.16%

Invesco Biotechnology & Genome ETF

2.22%

ALPS Medical Breakthroughs ETF

2.12%

Invesco S&P SmallCap Health Care ETF

1.69%

Virtus LifeSci Biotech Products ETF

1.63%

Invesco S&P SmallCap 600 GARP ETF

1.14%

SPDR S&P Biotech ETF

1.07%

Invesco S&P SmallCap Quality ETF

0.67%

Ver Mais

Alger Weatherbie Enduring Growth ETF

Proporção3.79%

iShares Neuroscience and Healthcare ETF

Proporção3.51%

First Trust NYSE Arca Biotechnology Index Fund

Proporção3.16%

Invesco Biotechnology & Genome ETF

Proporção2.22%

ALPS Medical Breakthroughs ETF

Proporção2.12%

Invesco S&P SmallCap Health Care ETF

Proporção1.69%

Virtus LifeSci Biotech Products ETF

Proporção1.63%

Invesco S&P SmallCap 600 GARP ETF

Proporção1.14%

SPDR S&P Biotech ETF

Proporção1.07%

Invesco S&P SmallCap Quality ETF

Proporção0.67%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados